Cargando…
An open-label, two-period comparative study on pharmacokinetics and safety of a combined ethinylestradiol/gestodene transdermal contraceptive patch
We investigated the pharmacokinetics and safety profiles of a newly developed combined ethinylestradiol (EE)/gestodene (GSD) transdermal contraceptive patch after a single-dose administration and compared with the market available tablet formulation in healthy adult subjects. An open-label, two-peri...
Autores principales: | Zhang, Chao, Li, Haiyan, Xiong, Xin, Zhai, Suodi, Wei, Yudong, Zhang, Shuang, Zhang, Yuanyuan, Xu, Lin, Liu, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354542/ https://www.ncbi.nlm.nih.gov/pubmed/28331292 http://dx.doi.org/10.2147/DDDT.S131123 |
Ejemplares similares
-
Ethinylestradiol/gestodene: Isolated cortical cerebral venous thrombosis: case report
Publicado: (2021) -
Pharmacokinetics of transdermal buprenorphine patch in the elderly
por: Al-Tawil, Nabil, et al.
Publicado: (2012) -
Satisfaction and compliance in hormonal contraception: the result of a multicentre clinical study on women's experience with the ethinylestradiol/norelgestromin contraceptive patch in Italy
por: Crosignani, Pier Giorgio, et al.
Publicado: (2009) -
Permeation measurement of gestodene for some biodegradable materials using Franz diffusion cells
por: Liu, Danhua, et al.
Publicado: (2015) -
Investigation of the Hemostatic Effect of a Transdermal Patch Containing 0.55 mg Ethinyl Estradiol and 2.1 mg Gestodene Compared with a Monophasic Oral Contraceptive Containing 0.03 mg Ethinyl Estradiol and 0.15 mg Levonorgestrel: An Open-Label, Randomized, Crossover Study
por: Junge, Wolfgang, et al.
Publicado: (2013)